SCHEMBL7861271

SCHEMBL7861271

C=CC(/C=C\c1ccc(C)cc1)c1ccc(O)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAOB P27338 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
MAOA P21397 1/20 0.44
RAB9A P51151 1/20 0.44
ACHE P22303 1/20 0.42
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
PTGS2 P35354 2/20 0.39
ALOX5 P09917 1/20 0.39
PTGS1 P23219 1/20 0.39
APP P05067 4/20 0.37
CA1 P00915 1/20 0.37
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
AKR1B10 O60218 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13558420 1.00 CYP3A4 (0.46) CYP3A4CYP2C9CYP2C19MAOBPOLB
Nyasol SCHEMBL8416158 0.92 APP (0.43) CYP3A4CYP2C9CYP2C19MAOBPOLB
Nyasol SCHEMBL30712027 0.92 APP (0.43) CYP3A4CYP2C9CYP2C19MAOBPOLB
Nyasol SCHEMBL776219 0.92 APP (0.43) CYP3A4CYP2C9CYP2C19MAOBPOLB
Nyasol SCHEMBL799383 0.92 APP (0.43) CYP3A4CYP2C9CYP2C19MAOBPOLB
Nyasol SCHEMBL776218 0.92 APP (0.43) CYP3A4CYP2C9CYP2C19MAOBPOLB
SCHEMBL7864584 0.83 MAPT (0.50) CYP3A4CYP2C9CYP2C19MAPTRAB9A
SCHEMBL7861615 0.83 MAPT (0.50) CYP3A4CYP2C9CYP2C19MAPTRAB9A
SCHEMBL805124 0.83 MAPT (0.50) CYP3A4CYP2C9CYP2C19MAPTRAB9A
SCHEMBL799612 0.83 MAOB (0.39) CYP3A4CYP2C9CYP2C19MAOBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120277169-A1 NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES BIONOVO, INC. (US) 2012-11-01 US disclosed
US-20090312274-A1 Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases BIONOVO, INC. (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312274-A1 Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases ESR2, ESR1, ESRRA CYP3A4 3838/4885CYP2C9 4584/4885CYP2C19 3750/4885
US-20120277169-A1 NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES ESR2, ESR1, ESRRA CYP3A4 3838/4885CYP2C9 4584/4885CYP2C19 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.